Annual report pursuant to Section 13 and 15(d)

Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)

v3.20.2
Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)
$ in Thousands
Jun. 30, 2020
Jun. 30, 2019
Total Assets $ 124,268 $ 65,147
Contingent consideration 6,137 12,600
Derivative instruments - cash flow hedges 17,331 12,458
Total Liabilities 23,468 25,058
Fair Value, Inputs, Level 1 [Member]    
Total Assets 116,272 65,147
Contingent consideration 0
Derivative instruments - cash flow hedges 0
Total Liabilities 0 0
Fair Value, Inputs, Level 2 [Member]    
Total Assets 7,996 0
Contingent consideration 0
Derivative instruments - cash flow hedges 17,331 12,458
Total Liabilities 17,331 12,458
Fair Value, Inputs, Level 3 [Member]    
Total Assets 0 0
Contingent consideration 6,137 12,600
Derivative instruments - cash flow hedges 0
Total Liabilities 6,137 12,600
Equity Securities [Member]    
Investments, Fair Value Disclosure [1] 87,842 38,219
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
Investments, Fair Value Disclosure [1] 79,846 38,219
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Investments, Fair Value Disclosure [1] 7,996 0
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]    
Investments, Fair Value Disclosure [1] 0 0
Certificates of Deposit [Member]    
Investments, Fair Value Disclosure [2] 36,426 26,928
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]    
Investments, Fair Value Disclosure [2] 36,426 26,928
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]    
Investments, Fair Value Disclosure [2] 0 0
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]    
Investments, Fair Value Disclosure [2] $ 0 $ 0
[1] Included in available-for-sale investments on the condensed consolidated balance sheet. The cost basis in the Company's investment in ChemoCentryx Inc (CCXI) was $7.6 million and $18.8 million as of March 31, 2020 and June 30, 2019, respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $5.6 million as of March 31, 2020. The fair value of the warrant as of June 30, 2019 was not material.
[2] Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one year.